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Background: Adverse drug reactions (ADRs) are a significant cause of morbidity and 
mortality, with many being identified post-marketing. Improvement in current ADR reporting, 
including utility of underused or innovative methods, is crucial to improve patient safety and 
public health.
Objectives: To evaluate methods to improve ADR reporting via a systematic literature 
review.
Methods: Data sources were Medline, Embase, Cochrane Library and National Library for 
health searches on ADR reporting (January 1997 to August 2007) including cross-referenced 
articles. Twenty-four out of 260 eligible studies were identified and critically assessed. Studies 
were grouped as follows: i) spontaneous reporting (11); ii) medical chart/note review (2); iii) 
patient interviews/questionnaires (3); and iv) combination methods including computer-assisted 
methods (8).
Results: Using computerized monitoring systems (CMS) to generate signals associated with 
changes in laboratory results with other methods can improve ADR reporting. Educational 
interventions combined with reminders and/or prescription card reports can improve hospital-
based ADR reporting, and showed short to medium term improvement.
Conclusions: The use of electronic health data combined with other methods for ADR reporting 
can improve efficiency and accuracy for detecting ADRs and can be extended to other health 
care settings. Although methods with educational intervention appear to be effective, few studies 
have reviewed long-term effects to assess if the improvements can be sustained.
Keywords: adverse drug reaction, reporting, ADR
Introduction
The World Health Organization (WHO) defines adverse drug reactions (ADRs) as 
“a response to a drug which is noxious and unintended, and which occurs at doses 
normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for 
the modification of physiological function”.1 ADRs lead to considerable morbidity 
and mortality worldwide. A study examining hospital-based admissions for ADRs 
estimated ADR-related hospital admissions to be as high as 6.5%,2 although certain 
patient groups (children and obstetric and gynecology related admissions) were 
excluded. ADRs were shown to be directly or indirectly associated with as many as 
100,000 deaths per year in the USA.3 In England, hospital episode statistics (HES) data 
showed that between 1998 and 2005 there were 447,071 ADRs representing 0.50% 
of total hospital episodes; over this period the number of ADRs increased by 45%.4 
Hence, ADRs have a major impact on public health, reducing patients’ quality of life 
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and increasing mortality and morbidity, whilst at the same 
time imposing a considerable financial burden on health care 
systems. A recent National Confidential Enquiry into Patient 
Outcome and Death (NCEPOD) report provided an analysis 
of 649 cancer patients who died within 30 days of receiving 
chemotherapy in UK hospitals,5 which further highlights the 
profile of serious ADR reporting.
Although some ADRs become apparent during clinical 
trials, many ADRs are not identified until the post-
marketing stage. The sample sizes in most clinical trials 
are often too low for the detection of rare ADRs, and are 
unable to detect ADRs with long latency periods. Most 
systems utilized for post-marketing drug surveillance rely 
primarily on spontaneous reporting. Examples of such 
systems include the Yellow Card scheme in the UK, which 
is managed by the Medicines and Healthcare products 
Regulatory Agency (MHRA), Medwatch in the US, man-
aged by the Food and Drug Administration (FDA) and the 
Uppsala Monitoring Centre in Sweden, which is the base 
for the WHO program for International Drug Monitoring. 
Typically, signals are identified using disproportionality 
measures such as the reporting odds ratio (ROR) which 
can be used to estimate relative risk, or the proportional 
reporting ratio (PRR): proportion of spontaneous reports 
for a selected drug related to a specific adverse outcome, 
divided by the corresponding proportion for all or several 
other drugs.
There are several limitations with spontaneous reporting 
databases. Although spontaneous reporting provides data 
on a broad spectrum of patients, the absence of a control 
group and lack of denominator data mean rate of ADRs 
cannot be accurately calculated.6,7 A significant problem 
lies with under-reporting and biases inherent in clinicians’ 
decisions to report ADRs. Various factors have been found 
to contribute to under-reporting, with examples including: 
i) lack of awareness on the purpose of ADR monitoring 
and how to report ADRs; ii) limited access to yellow cards 
(although online reporting is now available); iii) uncertainty 
of reactions being caused by drugs; iv) considering ADRs to 
be too common or trivial to report; and v) time constraints 
on clinicians.8,9 Bias due to media coverage of selected 
ADRs, and lack of verification of reported diagnoses further 
limits the data.
New opportunities involve computer-based surveillance 
methods particularly for hematological, renal, or hepato-
toxic ADRs from either secondary or primary care. The key 
advantages are systematic flagging of abnormal results which 
warrant further investigation by the responsible physician. 
This article discusses relative strengths and weaknesses of 
studies using computerized monitoring systems (CMS) in 
more detail later.
Methods
We evaluated methods to improve ADR reporting via a 
systematic literature review. We searched Medline, the 
Cochrane Library, Embase and the National Library of Health 
for studies examining methods of improving the reporting 
of adverse drug reactions published between January 1997 
and August 2007. The search strategy used the key MeSH 
terms and keywords: “adverse drug reactions” OR “adverse 
drug reaction reporting” OR “adverse drug reaction report-
ing systems”. The search was limited to English language 
studies. The types of articles included clinical trials, meta-
analyses, randomized controlled trials, comparative studies 
and reviews (Figure 1).
Two reviewers independently selected articles for inclu-
sion from those retrieved by our search. We assessed the 
studies that met our eligibility criteria as described below. 
Specifically, for trials this included randomization, allocation 
concealment, intention to treat analysis and completeness of 
follow up. Other than trial data we also included studies that 
met the inclusion criteria and examined methods to improve 
ADR reports rather than simply reporting prevalence or inci-
dence of ADRs. These papers included data from a number 
of sources and study groups. We included papers in which 
the interventions used were described in detail with defined 
outcome measures.
This search strategy resulted in the identification of 260 
studies. Of these 260 studies, 217 were excluded by reviewing 
the abstract or the title (the majority of these articles were 
descriptive of incidence or prevalence of ADRs), resulting 
in 43 potentially eligible studies. Nineteen studies were 
eligible for inclusion after reviewing the full articles; five 
further studies were identified from the reference sections 
of these studies.
Study selection
Inclusion criteria were studies that: i) evaluated or com-
pared methods of ADR reporting; ii) were Europe- or North 
America-based. Exclusion criteria were studies that: i) were 
based on unverified patient self reports; ii) evaluated medi-
cation errors or prescribing errors specifically; iii) aimed at 
calculating incidence of ADRs; iv) aimed at identifying 
specific ADRs; v) aimed at ways of reducing the occurrence 
of ADRs; vi) described obstacles to ADR reporting; and 
vii) were purely theoretical papers.
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Studies were grouped by method of ADR detection. 
These were: i) spontaneous reporting and routinely collected 
data, with or without intervention; ii) note-based and chart 
reviews; iii) interviews, questionnaires, or observers; and iv) 
combined methods including computer-assisted methods. 
For each study, information was collected on: the country 
in which it was carried out, study type, study period, sample 
size, the health care professional (HCP) being targeted, the 
mechanism which was being tested, the outcome measures, 
and the main conclusions with statistical analysis.
results
Of the 24 articles selected, four articles were related to 
trials. For the trials reviewed (including meta-analysis, 
a total of eleven trials), outcomes included ADR report-
ing rates, quality measures of reporting,10–12 and relative 
Database search 
217 excluded by reviewing the titles and/or abstracts 
24 studies excluded by reviewing full text articles 
5 Articles added from reference lists 
260 articles using selected 
search strategy 
43 articles 
19 articles 
24 articles 
11 articles  
Spontaneous reporting 
methods with or without interventions 
2 articles  
Studies using note/ 
chart review 
3 articles  
Methods using interviews 
Questionnaires
8 articles 
Combination methods/
CMS 
Figure 1 Article selection process for systematic review on ADr reporting.
Abbreviations:  ADr, adverse drug reactions; CMS, computerized monitoring systems.
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frequencies and rank order of ADR compared with different 
reporting methods.7 Two trials used interventions such as an 
educational lecture.10,11 A review of randomized controlled 
trials (RCTs) compared spontaneous reporting versus 
solicited collection methods for ADR reports.12 A meta-
analysis used six double-blind, placebo-controlled RCTs 
to assess frequencies of amiodarone-related ADRs.7 Details 
of intention to treat analyses were described,7,10 however, 
for the others it was unclear whether an intention to treat 
analysis was used.
From the individual trials, one explicitly stated a sample 
size calculation to determine numbers of participants to 
recruit.10 Exclusion criteria were given in two papers (seven 
trials).7,10
Discussion
Spontaneous reporting methods 
with or without interventions
Several studies examined interventional or comparative SR 
with other data; however there were only two RCTs.10,11 
The most commonly used interventions were verbal and 
written reminders; supplemented with yellow card placement. 
Although most intervention studies demonstrated an 
improvement in ADR reporting, in the largest RCT, follow 
up was limited to 16 months and so longer term outcomes 
could not be assessed. Other trained health professionals 
(nurses and medical students) showed competency in ADR 
reporting with appropriate interventions,11,13 but in general 
were based on small numbers with limited follow up time. 
Many studies also lacked control groups. There is potential 
to increase the scope of SR with online yellow card reporting 
now available both for health care professionals and patients 
in the UK and US, although the reports may be of variable 
quality, with little formal evaluation.
Measures of disproportionality
Currently, drug regulators use numerator dependent methods 
such as ROR, PRR, and Bayesian probability based data min-
ing tools as denominator data is often unavailable.6 Assuming 
statistical independence between drug and event, they assess 
the deviation of the reporting frequency from the expected. 
However recent evaluation of the WHO Bayesian approach 
showed good overall sensitivity but rather low specificity, 
limited by the small number of occurrences of each drug-
event association in the database,14,15 and may yield false 
positives.6,16 van Puijenbroek17 examined concordance of 
various measures of disproportionality using SR databases 
including a variety of measures compared to the Bayesian 
Confidence Propagation Neural Network (BCPNN) analysis. 
The BCPNN is a probability based approach using linked 
and new data fields used by the Uppsala Monitoring Centre 
as a reference measure, yielding an “information component 
(IC)”. The different measures were all highly sensitive but 
had low specificities compared to the BCPNN analysis, 
especially with low numbers of reports. Although they were 
all broadly comparable when four or more reports per com-
bination were present, this was only applicable in 11.2% of 
Dutch SR cases (unvalidated).17
Educational interventions
McGettigan reviewed the effect of increasing availability of 
yellow cards on wards in Dublin teaching hospitals, Ireland 
by sending them to prescribers (430 participating doctors) and 
placing them in drug charts. In addition, verbal and written 
reminders to doctors about ADR reporting were employed. 
A four-fold increase in reporting rates was demonstrated, 
but rates reverted to baseline once the intervention was 
removed.18 The increased reporting could be have been 
attributed to the questionnaire that was sent out about ADR 
reporting as opposed to the reminders and increased avail-
ability of yellow cards. This may have had a confounding 
effect, as well as seasonal variation bias.
A similar retrospective time series study with 30,000 
participating physicians between 1983 and 1995 by Castel 
showed a 58% increase in mean monthly reporting rates by 
sending quarterly bulletins about ADR reporting and improv-
ing yellow card availability; which declined to 36% and 
18% in the second and third month respectively, but lacked 
a control group. The bulletins were initially sent out quarterly 
by the end of 1985 however subject to potential confounding, 
as mailings later varied to monthly or bimonthly.19 Other 
confounding factors which were not assessed included the 
number of new drugs marketed, seasonal effects, population 
changes, potential reporter training, and variable bulletin 
content. The inclusion of yellow cards in prescription pads 
may not have been effective as only 22% of prescribers in 
the catchment area actually used these pads.
Clarkson compared numbers of yellow cards submitted 
before and after monthly reminder letters, in addition to 
spare yellow cards being sent to physicians and establishing 
a pilot Paediatric Regional Monitoring Centre (PRMC) as an 
extension of the UK’s spontaneous ADR reporting scheme. 
A 2.8-fold increase in the number of yellow cards received 
was shown over a 12 month period.20 It may be easier to 
identify ADRs in children, who tend to have fewer medicines 
prescribed, however only 19% of the reports had ADRs that 
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were considered to be medically significant, suggesting vari-
able quality of the reports. The existence of a PRMC may 
not be generalizable to general practitioners and no control 
group was examined.
Morrison-Griffiths evaluated the quality of three dif-
ferent nursing group ADR reports, compared to doctors 
in a UK setting. Nurses were given information packs and 
attended one-hour teaching sessions on ADR reporting.13 
Seventy-seven percent of nurses’ reports were judged as 
“appropriate” according to the criteria established by the 
regulatory authority compared to 69% of doctors’ reports, 
and comparable with doctors for causality 97% and 98% 
respectively using Naranjo criteria;21 (there are more recent 
recommendations on causality reporting from the WHO). 
However it is unclear whether the results are due to effects 
of the educational intervention they received, as there was no 
control group. Nurses only submitted reports with agreement 
of the responsible clinician, although only 3/373 (1%) cards 
were blocked in this way.
Barrow carried out a descriptive study to compare HES 
data for ADRs leading to admissions with spontaneously 
reported ADRs using UK yellow card data between 1996 and 
2000. MedDRA codes were identified for the relevant HES 
discharge diagnoses coded using ICD-10 codes. In particular, 
HES was more likely to identify drug-induced nephropathy, 
drug-induced aplastic anemia, dystonia, and Parkinsonism 
than yellow card data.22 The study showed that more ADRs 
are more likely to be recorded in the HES database compared 
to the yellow card database (apart from ototoxic hearing 
loss and hemolytic anemia), which may reflect seriousness 
of ADR (for example warfarin-related bleeding). This may 
be because it is compulsory to report patient episodes in the 
HES database; however the information recorded is often 
completed by the most junior medical team member or by 
administrative staff. Furthermore, ICD-10 codes used for 
diagnostic coding in the HES database often lack specificity. 
HES data contains details of all admissions to NHS hospitals 
in England, but the yellow card database is used throughout 
the UK. The matching process for both datasets in terms of 
time, place, and codes was also imperfect as terminology 
was different. Despite these limitations the HES database 
has good potential in being utilized as a mechanism for ADR 
reporting and monitoring.
Bousquet compared a new approach of signal detection 
which integrated hierarchical groups and Bayesian measures 
for signal generation, with the standard method using the 
MedDRA terms from over 42,000 reports from the French 
SR database. Five measures of automated signal detection 
were applied using each method and the mean frequency 
of drug-adverse effect associations compared. Using these 
enhanced methods for signal detection, the numbers identified 
were significantly higher but lacked external validation. The 
highest mean number of occurrences was found combining 
the ontology terminological reasoning (TR) and approximate 
matching (AM) methods (3.63), with significant differences 
in the mean number of occurrences between approaches 
(p  0.001).23 Bousquet’s study was limited as the signals 
generated by each method were unvalidated by other SR 
systems. Therefore, although more signals were generated 
by applying the new algorithms, there was no distinction 
between irrelevant “noise” and relevant signals.
Causality assessment of ADrs
Macedo compared different algorithms by assessing agree-
ment between them, using the WHO “GI” standard method 
with decisional algorithms using general practitioners (GPs) 
and pharmacists. The kappa index of reliability was used 
to quantify the extent to which the observed proportion of 
agreements exceeded the proportion of agreements expected 
by chance alone. This was 0.26, suggesting a high probability 
of agreements being due to chance, particularly where the 
number of reports was below four.24 Confounding factors not 
considered when evaluating algorithms could have accounted 
for the low concordance.
Figueiras conducted a cluster RCT over a 16-month 
period in Northern Portugal, covering all National Health 
System physicians which showed a significant (10-fold) 
increase in reporting rates following education interven-
tion and reminder cards, however the effect only remained 
significant for a year. At the end of the study, there was a 
significant increase in reports submitted by the intervention 
group (p  0.001). After 13 months, this difference became 
less significant (p = 0.07) indicating that the duration of the 
effect of the intervention is time-dependent. Intervention 
also improved report quality by increasing the reporting rate 
for serious, high causality, unexpected and new drug-related 
ADRs.10 The risk of cross-contamination between groups 
was minimized by using a cluster-based distribution, and 
by adjusting for unequally distributed variables. However 
the study was limited as only 47.2% of physicians assigned 
to the intervention group actually attended the lecture, sug-
gesting a potentially greater effect with higher attendance, 
and long term benefits were not assessed. Rosebraugh also 
noted improvement quality of reports by fourth year medical 
students following a 15 minute lecture on ADR reporting, 
although there was no long term follow-up.11
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Methods using note/chart review
Several studies have used chart review either alone or in 
combination with other methods; the main disadvantage is 
the intensive time resource required.
Lata25 showed that introducing and educating nursing case 
managers (NCMs) using chart review and patient interviews 
led to an increase in ADR reporting rates from 1998–2001, 
(2.1–5.3 per 100 admissions) although other confounding 
factors that may have affected this rise were not considered, 
including the number of new medications licensed and other 
incentives about ADR reporting. It is impossible to know 
the number of ADRs missed by the reporting system and 
therefore the sensitivity. The skills for NCMs were not stan-
dardized and might have differed between settings, limiting 
generalizability of results. This study resulted in increased 
awareness of radio-contrast related ADRs and policy change 
regarding warfarin-related ADRs.25
Hougland used retrospective chart review to assess the 
validity of ICD-9-CM codes for detecting ADRs, examin-
ing 1142 inpatient charts in a US hospital. The overall 
PPV for a flagged code representing an ADR was 66%, 
comparing favorably with existing CMS. However, sensi-
tivity of flagged codes for inpatient ADRs was only 10% 
(rates were higher at 55% for hospital admission-related 
ADRs) indicating that the selected codes only detect a 
minority of inpatient ADRs. The specificity was 97% in 
both groups. Bias may have resulted by introducing terms 
such as “poisoning” for certain medication errors within 
the ICD nomenclature. This might have influenced hospital 
coders due to liability related to documenting a poisoning 
event. Codes could potentially be improved by removing 
those with poor PPVs and adding relevant additional codes 
determined by reviewers.26
Methods using interviews/questionnaires
Overall detailed questioning may help elicit potential ADRs 
but many studies are small, lack validation and may not be 
generalizable.27,28
Somers compared patient interviews by pharmacists 
with spontaneous reporting by nurses and physicians to 
detect ADRs in elderly hospital ward patients in Belgium. 
Somers demonstrated that solicited patient interviews 
by pharmacists yielded more ADRs 57% (32/56; 98% 
classified a probable or possible with 59% of these resulting 
in an intervention) than spontaneous reporting by nurses 
and physicians 4.8% (8/168), however a higher propor-
tion of ADRs reported spontaneously resulted in medical 
intervention (92%). This may indicate that spontaneous 
reports yield a greater amount of severe ADRs that need 
medical action compared to reports from interviews 
classified as severe. This study had some internal validity 
as all reports were discussed weekly with the physician to 
assess causality, severity, type and level of intervention. 
The exclusion of sick and confused patients may have 
affected the results as the confusion may have been a result 
of an ADR. Combining both methods would probably be 
more useful for examining ADR occurrence.29 Aspinall 
compared numbers of ADRs by telephone interview on 
a randomly selected population sample of 198 patients 
and passive spontaneous voluntary reporting in the US. 
Although the follow up was only two months; 83 ADR 
were identified by telephone interview (99% classified as 
probable or possible), compared to just a single spontane-
ous report. Aspinall demonstrated a higher ADR reporting 
rate using patient telephone interviews compared to passive 
voluntary spontaneous reporting. This study was limited as 
it was based at a single academic tertiary care hospital and 
only included one reviewer.27 Medical staff were unaware 
of nearly half of the ADRs that patients suspected, despite 
having reviewed the patient in an outpatient appointment 
within the previous 72 hours, suggesting ADRs could be 
missed, possibly due to time constraints and inadequate 
medication review.
Greenhill compared different questioning methods 
by US physicians to identify ADRs in children receiving 
psychotropic medications. The general inquiry (GI) was used 
initially, sequentially followed by the drug-specific inquiry 
(DSI) and the comprehensive body system review (BSR). 
195 ADRs were identified during 59 patient interviews and 
the study showed systematic elicitation of ADRs, organized 
by body systems, increased the identification of clinically 
relevant ADRs that may not be detected by general inquiry, 
although statistical differences were not assessed. However 
the ADRs identified were not validated, and questioning 
order effects not considered. The sample size was also small 
affecting the study’s power and based on children using 
psychotropic medications only, limiting generalizability.28
Combination methods
Computerized monitoring systems
CMS are not currently widely used because of lack of experi-
ence, uncertainty about efficiency, and lack of appropriate 
technology. There were eight studies selected which used 
combination methods; five of which include the use of CMS. 
Although these studies showed a low predictive value for 
signals generated by the CMS, with refinement of the signals, 
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this may improve. Chart review, although better at identifying 
ADRs, has the disadvantages of being expensive and time-
dependent, with limited scope for intervention. CMS can be 
prospective, allowing early detection and intervention in drug 
therapy. It involves less staff and has been shown to detect 
more ADRs than stimulated spontaneous reporting (SSR). 
In general methods to improve ADR reporting have been 
most successful when combined with CMS. Additionally, 
many software programs exist to implement automated signal 
detection in post-marketing databases.6
Jha carried out an eight-month prospective cohort study 
in a tertiary care teaching US hospital to compare ADRs 
detected by a CMS, chart review and stimulated voluntary 
reporting, and found that computer-based methods identified 
fewer ADRs (45%) than chart review (65%), but more than 
voluntary reporting (4%). The PPV of computer-generated 
alerts was 16% initially, but after later changing rules (9/49), 
this increased to 23%. This study demonstrated that the types 
of events captured by computer monitoring are substantially 
different to those captured by chart review. The advantages 
of this study are that it was prospective in nature and that 
the independent reviewers assessing the likelihood of alerts 
being due to ADRs, were blinded to the data generated by 
the computer monitor to limit bias.30 Limitations include the 
absence of a gold standard for comparison.
Dormann used a prospective cohort study over six months 
to compare a CMS for automatically generated laboratory 
signals with SSR in a German university hospital. Both 
CMS signals and SSRs were validated by the pharmaco-
epidemiological team, using chart review. The PPV of 
automatically generated laboratory signals by the CMS was 
13%. The sensitivity and specificity of the CMS was 74% 
and 75%, respectively. The sensitivity of SSR was 37% but 
the specificity was higher at 98%.31
In this study, due to absence of denominator data, only 
the relative sensitivity could be determined. Certain ADRs, 
for example, signals indicating hematological pathology 
or drug concentration, had higher PPVs (17%–25%) and 
were more frequently associated with an ADR than other 
signals. SSR was most effective in detecting clinical 
symptoms such as gastrointestinal side effects, whereas 
the CMS more reliably identified ADRs associated with 
quantitative changes in laboratory values such as nephro-
toxicity, hepatotoxicity, and hematological changes.31 In a 
later study, Dormann compared a CMS with prospective 
chart review over six months to detect possible ADRs by 
laboratory induced abnormalities. In addition, they com-
pared the PPV of different signals known as “new ALS” 
(automatic laboratory signal; the first value of a laboratory 
test outside the normal defined range); and “delta ALS” 
(a new value of a laboratory test which differed significantly 
from the previous value). The PPV of alerts categorized 
as “new ALS” varied between 13% for immunoglobulin 
E (IgE)-related allergy, and a maximum of 40% for change 
in electrolytes (calcium, potassium, sodium). The overall 
PPV of alerts categorized as “delta ALS” was higher (18% 
to 67%) for abnormalities in liver enzymes (ALP) and 
sodium and potassium levels, respectively. However, these 
were not as sensitive (40%) as using alerts generated using 
the 1st value of a laboratory test outside the normal defined 
range (sensitivity 91%). However, the specificity of alerts 
generated by the “new ALS” was lower at 23% compared 
to 76% with the “delta ALS”.32
Hope compared the use of a tiered approach to a tradi-
tional pharmacist based approach for identifying ADRs with 
patients attending ambulatory care clinics in Indianapolis 
and Boston. The tiered approach consisted of generating 
signals from electronic medical records by computer queries, 
followed by exclusion of some signals by nonclinical data 
managers who could also add data, subsequently reviewed 
by nurses and pharmacists. The alternative approach was 
pharmacist based review. Computer searches were used in 
both groups for the initial detection. There was no significant 
difference in PPVs (p = 0.36) by either approach, 10.2% 
(tiered) versus 9.6% (pharmacist), which were both low.33 
The tiered approach (although deemed cost-effective) is a 
complicated process that may be difficult to enforce and relies 
on availability, experience, and judgment of pharmacists. 
Confounding factors include that both sites had different 
patient populations with unstandardized electronic medical 
records, which suggests that lack of differences may not be 
attributable to the different approaches alone.
Haffner used a similar approach in a three-month 
prospective cohort study in a German teaching hospital 
to compare ADR reporting using intensified chart review 
and computer-assisted screening of pathological laboratory 
parameters. Chart review had a higher sensitivity at 67.2% 
when compared to computer-assisted screening (sensitivity 
44.8%). The specificity for intensified surveillance was not 
calculated but was 72.8% for computer-assisted screening 
with a mean PPV of signals of 18.6%. Computer assisted 
screening identified ADRs associated with hepatic or hema-
tological consequences, whereas intensified surveillance 
(however no details on training were given) identified more 
ADRs related to gastrointestinal, dermatological, and neuro-
logical symptoms, which was also confirmed in other studies. 
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Sensitivity was unreliable as it was based on the assumption 
that all ADRs are picked up by both methods.34
Neubert carried out a prospective pharmacoepidemiologi-
cal pediatric ward-based survey in a University hospital in 
Germany to evaluate a CMS which uses automatic laboratory 
signals as alerts for identifying ADRs in addition to spontane-
ous reporting by the treating physician. Although the sensi-
tivity of the CMS for ADRs was 90.3%, the specificity was 
only 19.6% indicating that although it identifies most ADRs, 
it might be generating additional noise. With alerts for relative 
laboratory result changes only (DELTA); although specific-
ity increased to 75.9%, sensitivity decreased to 50% which 
was similar to Dormann’s findings.32 This study was limited 
as laboratory tests were only performed when requested by 
the treating physician. Routine observation of ADRs by the 
practicing physician only identified 43% of ADRs, which 
increased when combining this method with CMS to 74%, 
however both methods failed to detect 26% of ADRs.35 These 
results suggest that implementing a CMS based on labora-
tory data was ineffective alone and should only be used as an 
adjunct to observation by the treating physician. In addition, 
certain ADRs only cause clinical symptoms, for example diar-
rhea; and these cannot be detected by the CMS. Conversely, 
some ADRs may only be detected by change in laboratory 
value, for example drug-induced neutropenia or anemia.
Other combination methods
Loke compared frequencies of ADRs to the antiarrhythmic 
drug, amiodarone using three different datasets generated 
from: i) a meta-analysis of RCTs; ii) published case reports; 
and iii) from spontaneous reports sent to the WHO. The 
distributions of ADR rank order and relative frequencies 
were dissimilar among the datasets. For example the highest 
rank order ADRs were cardiac in the dataset produced by 
the meta-analysis in contrast to respiratory and thyroid for 
case reports and spontaneous reports respectively. Results 
demonstrated poor concordance when comparing amiodarone 
ADR relative frequencies using datasets generated by a 
meta-analysis of six RCTs, case reports, and spontaneous 
reports sent to the WHO.7 Due to the strict selection criteria 
applied, only six RCTs were used, which limited the power 
of the meta-analysis. The strengths of the meta-analysis were 
that selection and detection bias were minimized as the RCTs 
were double-blinded and placebo-controlled. However, in the 
six RCTs, only 2,000 patients were treated with amiodarone 
which would reduce the likelihood of yielding useful informa-
tion on rare ADRs. Variation in the types of ADRs reported 
in the different RCTs could have led to some loss of precision 
when using a categorized summary of the data. Although 
357 case reports fulfilled the inclusion criteria for ADRs to 
amiodarone, the value of data produced by such reports is 
limited due to established reporting and publication bias.
Wernicke compared spontaneous and solicited ADR 
collection methods from three large randomized, double-
blind clinical-controlled trials ADRs in children, adolescents, 
and adults given either a drug or placebo. ADRs were either 
collected by unsolicited methods (spontaneously) where 
open-ended questions were asked, or by solicited methods 
where questionnaires consisting of detailed checklists were 
administered after spontaneous events were recorded. 
Solicited methods yielded higher rates of reporting for all 
29 ADRs identified. However, in 76% of ADRs, unsolicited 
methods (SR) had a greater ability to distinguish drug from 
placebo effects. This suggests that although the sensitivity 
might be greater using solicited methods, specificity may be 
compromised as prompting patients to report ADRs might 
stimulate reporting of insignificant symptoms.12 Lack of 
standardization of symptoms, diagnosis, drug, dosage and 
treatment duration may have also acted as confounding 
factors and may have affected the perception and reporting 
of ADRs. In addition, with spontaneous reports, patients 
might not report events which are transient or embarrassing 
and have resolved before their visit.
Limitations of our review
Although a systematic search of the literature was undertaken 
based on our selected criteria, some published and unpublished 
studies may have been omitted. Most of the studies had very 
short follow up times, and the longest trial included follow 
up for 16 months. Therefore we are unable to determine if 
improvements in ADR reporting are sustained long term.
We were also limited by the data available from the 
papers and the ability to combine studies due to the hetero-
geneous nature in the designs. Many studies did not include 
statistical interpretation of their results. We reported limited 
meta-analysis for two studies,7,12 but did not attempt a 
separate re-analysis. Because of the small number of studies, 
we were unable to find evidence for publication bias.
Conclusions
There are several limitations with current methods of ADR 
reporting. Most studies that have looked at the effect of 
educational intervention to improve spontaneous reporting 
have shown considerable improvement in rates, although 
this benefit decreases with time. Increasing the availability 
of yellow cards on wards as well as encouragement to use 
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web-based reporting may also improve reporting rates. 
Questionnaires, chart review and patient interviews can be 
a valuable source of information on ADRs, but are time 
and personnel dependent. Other factors that could influence 
reporting of ADRs are the quality of data in spontaneous 
reporting databases and the statistical methods employed to 
detect signals. Improving coding of terms to describe ADRs, 
to make them more specific and homogeneous, may improve 
quality of reports. Combining inpatient reviews with hospi-
tal-based CMS may better prospectively identify potential 
ADRs. CMS methods appear to have greater sensitivity than 
SR (possibly greater for those generated by the first value of 
a laboratory test outside the normal range); although in the 
studies we reviewed the positive predictive value was low. 
The PPV may be better for alerts generated by a laboratory 
value which differed significantly from the previous value. 
This could be explained by a number of factors and refine-
ment of the CMS approach such as including filters to exclude 
nondrug causes may help improve the results.
With health care systems becoming more computerized 
in both primary and secondary care, there is great potential 
to explore these systems for ADR detection. For example, 
the addition of a section for ADRs that occurred during the 
patient’s admission in electronic discharge summaries could 
improve ADR detection. The computerization of medical 
health records with prescription data covering several mil-
lion people can help promote developments of methods for 
detecting ADRs in clinical practice in the UK and other 
countries. Ongoing initiatives include the EU-ADR project, 
a FP7 multinational collaboration for the early detection and 
investigation of adverse drugs events,36 using data from a 
number of European medical databases.
The population of both developed and developing coun-
tries are gradually aging, with an increasing proportion of the 
population comprised of elderly people who are at greatest 
risk of suffering from chronic diseases. There is also greater 
pressure on clinicians to treat chronic diseases and their risk 
factors using evidence-based guidelines. Both these factors 
are increasing prescribing rates, promoting polypharmacy, 
and leading to an increased risk of drug interactions and 
ADRs. Accurate surveillance is an essential first step that 
must be undertaken to identify ADRs and implementing 
measures to reduce their public health impact.
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